23,960 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Acquired by Yarbrough Capital LLC

Yarbrough Capital LLC purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSFree Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 23,960 shares of the company’s stock, valued at approximately $567,000.

Other large investors also recently modified their holdings of the company. Parkman Healthcare Partners LLC raised its stake in NewAmsterdam Pharma by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares during the period. Opaleye Management Inc. bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth $2,964,000. Schonfeld Strategic Advisors LLC grew its position in NewAmsterdam Pharma by 12.9% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock valued at $598,000 after purchasing an additional 7,400 shares during the period. Wolverine Asset Management LLC increased its stake in NewAmsterdam Pharma by 197.2% during the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock valued at $97,000 after purchasing an additional 5,769 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in NewAmsterdam Pharma by 25.0% during the third quarter. Affinity Asset Advisors LLC now owns 125,000 shares of the company’s stock worth $1,156,000 after buying an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock traded up $0.79 during trading on Friday, hitting $18.02. The company’s stock had a trading volume of 191,165 shares, compared to its average volume of 206,817. The business has a fifty day moving average of $20.04 and a 200-day moving average of $18.79. NewAmsterdam Pharma has a 52 week low of $5.63 and a 52 week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $2.95 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -2.52 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 8,429 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The shares were acquired at an average price of $21.50 per share, for a total transaction of $181,223.50. Following the completion of the purchase, the director now owns 3,008,429 shares in the company, valued at $64,681,223.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Johannes Jacob Piete Kastelein sold 190,476 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $21.50, for a total value of $4,095,234.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James N. Topper purchased 8,429 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The shares were acquired at an average price of $21.50 per share, for a total transaction of $181,223.50. Following the completion of the purchase, the director now directly owns 3,008,429 shares in the company, valued at approximately $64,681,223.50. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on NAMS shares. Scotiabank initiated coverage on shares of NewAmsterdam Pharma in a research report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a report on Friday, June 7th. Finally, TD Cowen started coverage on NewAmsterdam Pharma in a report on Wednesday, May 15th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.25.

Check Out Our Latest Stock Report on NAMS

About NewAmsterdam Pharma

(Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

See Also

Institutional Ownership by Quarter for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.